We are live on
!
Find out more
CS
Candriam SCA Portfolio holdings
AUM
$19.3B
1-Year Est. Return
39.18%
This Fund
S&P 500
This Quarter
Est. Return
+4.06%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$8.02B
AUM Growth
+$201M
(+2.6%)
Cap. Flow
-$89M
Cap. Flow
% of AUM
-1.11%
Top 10 Holdings %
Top 10 Hldgs %
19.81%
Holding
867
New
76
Increased
308
Reduced
302
Closed
63
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vertex Pharmaceuticals
VRTX
|
+$48.8M |
| 2 |
Procter & Gamble
PG
|
+$24.6M |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$23.6M |
| 4 |
Keysight
KEYS
|
+$23.2M |
| 5 |
Bristol-Myers Squibb
BMY
|
+$21.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$46.5M |
| 2 |
ExxonMobil
XOM
|
+$36.6M |
| 3 |
GG
Goldcorp Inc
GG
|
+$24.9M |
| 4 |
Walt Disney
DIS
|
+$23.8M |
| 5 |
NAVG
Navigators Group Inc
NAVG
|
+$19.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 33.16% |
| 2 | Technology | 16.87% |
| 3 | Financials | 10.38% |
| 4 | Consumer Discretionary | 9.09% |
| 5 | Communication Services | 7.96% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
601
SEI Investments
SEIC
$11.9B
| $1.18M | 0.01% |
21
+1
| +5% | +$54 |
|
602
Iovance Biotherapeutics
IOVA
$2.23B
| $1.17M | 0.01% |
+48,000
| New | +$723K |
|
603
Ulta Beauty
ULTA
$20.4B
| $1.17M | 0.01% |
3,394
+12
| +0.4% | +$4.15K |
|
|
FTSV
604
DELISTED
Forty Seven, Inc. Common Stock
FTSV
| $1.16M | 0.01% |
109,612
-10,388
| -9% | -$152K |
|
605
ResMed
RMD
$28.3B
| $1.15M | 0.01% |
+9,501
| New | +$1.05M |
|
606
Kimco Realty
KIM
$17.6B
| $1.15M | 0.01% |
62,629
-1,099
| -2% | -$19.9K |
|
|
CBIO
607
Crescent Biopharma
CBIO
$602M
| $1.15M | 0.01% |
969
+235
| +32% | +$281K |
|
608
Extra Space Storage
EXR
$31.2B
| $1.15M | 0.01% |
10,877
+117
| +1% | +$12.3K |
|
|
ABMD
609
DELISTED
Abiomed Inc
ABMD
| $1.15M | 0.01% |
4,421
+660
| +18% | +$175K |
|
610
STAAR Surgical
STAA
$1.16B
| $1.14M | 0.01% |
39,000
| – | – |
|
611
Franco-Nevada
FNV
$41.4B
| $1.14M | 0.01% |
13,441
+2,731
| +25% | +$206K |
|
612
Arch Capital
ACGL
$36.1B
| $1.13M | 0.01% |
30,578
-203
| -0.7% | -$6.92K |
|
613
Alexandria Real Estate Equities
ARE
$8.88B
| $1.13M | 0.01% |
8
+4
| +100% | +$578 |
|
614
Assurant
AIZ
$13.7B
| $1.12M | 0.01% |
10,571
-22,031
| -68% | -$2.18M |
|
615
Mohawk Industries
MHK
$6.9B
| $1.12M | 0.01% |
7,623
-109
| -1% | -$15.1K |
|
616
TransUnion
TRU
$14.8B
| $1.12M | 0.01% |
15,248
| – | – |
|
|
WBK
617
DELISTED
Westpac Banking Corporation
WBK
| $1.12M | 0.01% |
56
-1
| -2% | -$19 |
|
618
Manulife Financial
MFC
$72.6B
| $1.1M | 0.01% |
60,684
-75,165
| -55% | -$1.34M |
|
619
Cooper Companies
COO
$13.7B
| $1.08M | 0.01% |
+12,828
| New | +$964K |
|
620
ManpowerGroup
MAN
$2.39B
| $1.06M | 0.01% |
11
-7,696
| -100% | -$701K |
|
621
Leidos
LDOS
$14.1B
| $1.06M | 0.01% |
+13,318
| New | +$973K |
|
622
Expeditors International
EXPD
$22.9B
| $1.06M | 0.01% |
13,985
+910
| +7% | +$68.7K |
|
623
NOV
NOV
$7.45B
| $1.05M | 0.01% |
47,534
-994
| -2% | -$24K |
|
624
Conagra Brands
CAG
$7.07B
| $1.05M | 0.01% |
39,622
-38,489
| -49% | -$1.12M |
|
|
AMTD
625
DELISTED
TD Ameritrade Holding Corp
AMTD
| $1.04M | 0.01% |
20,990
| – | – |
|
Similar funds
PCM
A
MGP
LF
SOMRS
BPA
MIM
Candriam SCA's Q2 2019 Portfolio in Review
As of Q2 2019, Candriam SCA held 867 positions worth $8.02B, up 2.6% from $7.82B the previous quarter. Its ten largest holdings account for 20% of the portfolio.
Candriam SCA's Q2 2019 filing shows 76 new, 308 increased, 302 reduced and 63 closed positions. Its largest new stake was Total System Services, Inc.: 112,342 shares worth $14.3M. The largest sale was Celgene Corp, an estimated $46.5M.
By sector, the portfolio is most concentrated in Healthcare at 33% of assets, down from 33% a quarter earlier, followed by Technology and Financials.
- Candriam SCA's largest Q2 2019 buy was Total System Services, Inc.: 112,342 shares worth $14.3M.
- Candriam SCA added most to Vertex Pharmaceuticals in Q2 2019, an estimated $48.8M increase.
- Candriam SCA's biggest Q2 2019 reduction was Celgene Corp, cutting an estimated $46.5M.
- Candriam SCA fully exited Goldcorp Inc in Q2 2019, selling an estimated $24.9M.
- Candriam SCA's ten largest holdings make up 20% of its $8.02B portfolio in Q2 2019.
- Candriam SCA opened 76 new positions and closed 63 in Q2 2019.
- Candriam SCA's portfolio value rose 2.6% quarter-over-quarter to $8.02B.
Based on Candriam SCA's 13F filing for Q2 2019, filed 1 Aug 2019.